COVID-19 and Anticoagulant Use: Did the Pandemic Push DOACs Ahead of Warfarin?

Abstract

The coronavirus disease 2019 (COVID-19) pandemic introduced unprecedented disruptions to health care delivery, compelling rapid adaptations in anticoagulation management. Direct oral anticoagulants (DOACs), already displacing warfarin due to their convenience and reduced monitoring requirements, appeared well-positioned for broader adoption during pandemic-induced lockdowns. This commentary examines whether the pandemic catalyzed a meaningful shift in anticoagulant prescribing patterns from vitamin K antagonists (VKAs) to DOACs, drawing on data from the United Kingdom, Australia, the United States, Europe, and Asia. In the United Kingdom, national guidance led to an abrupt and large-scale switch to DOACs, with sustained changes postpandemic. In contrast, Australia and the United States exhibited continuity in preexisting trends, with modest, transient shifts that did not persist. Asian and European data revealed a gradual trajectory toward DOACs, likely driven by long-term policy and infrastructure rather than acute pandemic pressures. While no universal transformation occurred, the pandemic accentuated existing preferences and exposed system-level vulnerabilities in warfarin monitoring. The global experience suggests that the COVID-19 crisis served as a selective accelerant of DOACs adoption, where health care systems and policies facilitated change. As health systems prepare for future disruptions, equitable access to DOACs and investment in remote care infrastructure will be essential to ensuring continuity and safety in anticoagulation therapy.

Keywords

DOACs - warfarin - anticoagulation - COVID-19 - telemedicine - atrial fibrillation - deep vein thrombosis

Authors' Contributions

B.E.F. conceptualized and wrote the first draft. All authors made substantial contributions to the conception and design of the manuscript, acquisition of data, analysis and interpretation of data, drafting the article, and revising it critically for important intellectual content. All authors approved the final version of the submitted manuscript.

Publication History

Received: 16 July 2025

Accepted: 27 July 2025

Accepted Manuscript online:
28 July 2025

Article published online:
18 August 2025

• References

• 1 Favaloro EJ, Pasalic L, Lippi G. Oral anticoagulation therapy: An update on usage and costs in the endemic COVID-19 era. J Clin Med 2025; 14 (08) 2591
• 2 National Health Service England. Clinical guide for the management of anticoagulant services during the coronavirus pandemic. 2020. Accessed April 27, 2025 at: https://www.nice.org.uk/media/default/about/covid-19/specialty-guides/specialty-guide-anticoagulant-services-and-coronavirus.pdf
• 3 Poli D, Tosetto A, Palareti G. et al.; On the behalf of Italian Federation of Anticoagulation Clinics (FCSA). Managing anticoagulation in the COVID-19 era between lockdown and reopening phases. Intern Emerg Med 2020; 15 (05) 783-786
• 4 Dale CE, Takhar R, Carragher R. et al.; CVD-COVID-UK Consortium. The impact of the COVID-19 pandemic on cardiovascular disease prevention and management. Nat Med 2023; 29 (01) 219-225
• 5 Oldenburg J, Klamroth R, Langer F. et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: Guidance statement from the GTH. Hamostaseologie 2021; 41 (03) 184-189
• 6 Pavord S, Scully M, Hunt BJ. et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021; 385 (18) 1680-1689
• 7 Alkhameys S, Barrett R. Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021). Curr Med Res Opin 2022; 38 (07) 1081-1092
• 8 Curtis HJ, MacKenna B, Walker AJ. et al.; OpenSAFELY Collaborative. OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic. Open Heart 2021; 8 (02) e001784
• 9 Patel R, Czuprynska J, Roberts LN. et al. Switching warfarin patients to a direct oral anticoagulant during the coronavirus disease-19 pandemic. Thromb Res 2021; 197: 192-194
• 10 Kurdi A, Albutti A, Darweesh O. et al. Impact of COVID-19 pandemic on the prescribing pattern of oral anticoagulants in the English primary care setting: a population-based segmented interrupted time series analysis of over 53 million individuals. Expert Rev Clin Pharmacol 2025; 18 (04) 237-246
• 11 Favaloro EJ, Clifford J, Leitinger E. et al. Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients. J Thromb Haemost 2022; 20 (12) 2896-2908
• 12 Favaloro EJ, Pasalic L, Lippi G. Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing. Pathology 2017; 49 (06) 639-643
• 13 Navar AM, Kolkailah AA, Overton R. et al. Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. J Am Heart Assoc 2022; 11 (22) e026723
• 14 Barnes GD, Burnett A, Allen A. et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2020; 50 (01) 72-81
• 15 Hernandez I, Gabriel N, He M. et al. COVID-19 and Anticoagulation for Atrial Fibrillation: An analysis of US Nationwide Pharmacy Claims Data. J Am Heart Assoc 2021; 10 (24) e023235
• 16 Pearson LN, Johnson SA, Greene DN. et al. Side-effects of COVID-19 on patient care: An INR story. J Appl Lab Med 2021; 6 (04) 953-961
• 17 Peduzzi B, Hill MG, Hamilton J. et al. Drive-through point-of-care INR testing: Novel concepts for delivery of care during the COVID-19 pandemic. Am J Health Syst Pharm 2022; 79 (01) e4-e7
• 18 Hernandez I, Yang L, Tang S. et al. COVID-19 pandemic and trends in clinical outcomes and medication use for patients with established atrial fibrillation: A nationwide analysis of claims data. Am Heart J Plus 2024; 42: 100396
• 19 Akao M, Ogawa H, Masunaga N. et al.; Fushimi AF Registry Investigators. 10-Year trends of antithrombotic therapy status and outcomes in Japanese atrial fibrillation patients - The Fushimi AF Registry. Circ J 2022; 86 (04) 726-736
• 20 Samuelsen PJ, Wettermark B, Nyberg F, Hajiebrahimi M. Correction to ‘Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis’. Basic Clin Pharmacol Toxicol 2025; 136 (06) e20001